137 related articles for article (PubMed ID: 18183587)
1. Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate.
Okamoto Y; Liu X; Suzuki N; Okamoto K; Sekimoto M; Laxmi YR; Shibutani S
Int J Cancer; 2008 May; 122(9):2142-7. PubMed ID: 18183587
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.
Balaburski GM; Dardes RC; Johnson M; Haddad B; Zhu F; Ross EA; Sengupta S; Klein-Szanto A; Liu H; Lee ES; Kim H; Jordan VC
Int J Oncol; 2010 Aug; 37(2):387-98. PubMed ID: 20596666
[TBL] [Abstract][Full Text] [Related]
3. Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions.
Laxmi YR; Liu X; Suzuki N; Kim SY; Okamoto K; Kim HJ; Zhang G; Chen JJ; Okamoto Y; Shibutani S
Int J Cancer; 2010 Oct; 127(7):1718-26. PubMed ID: 20073065
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091
[TBL] [Abstract][Full Text] [Related]
5. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T
Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561
[TBL] [Abstract][Full Text] [Related]
6. Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen.
Suzuki N; Liu X; Laxmi YR; Okamoto K; Kim HJ; Zhang G; Chen JJ; Okamoto Y; Shibutani S
Int J Cancer; 2011 Feb; 128(4):974-82. PubMed ID: 20824696
[TBL] [Abstract][Full Text] [Related]
7. Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models.
Brady H; Desai S; Gayo-Fung LM; Khammungkhune S; McKie JA; O'Leary E; Pascasio L; Sutherland MK; Anderson DW; Bhagwat SS; Stein B
Cancer Res; 2002 Mar; 62(5):1439-42. PubMed ID: 11888917
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma.
Lamb CA; Helguero LA; Fabris V; Lucas C; Molinolo AA; Lanari C
Breast Cancer Res Treat; 2003 May; 79(1):25-35. PubMed ID: 12779079
[TBL] [Abstract][Full Text] [Related]
9. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.
Saarinen NM; Wärri A; Dings RP; Airio M; Smeds AI; Mäkelä S
Int J Cancer; 2008 Sep; 123(5):1196-204. PubMed ID: 18528864
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
[TBL] [Abstract][Full Text] [Related]
11. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
12. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
Terakawa N
Oncology; 2000; 59 Suppl 1():3-4. PubMed ID: 11096349
[No Abstract] [Full Text] [Related]
13. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.
McDougal A; Wormke M; Calvin J; Safe S
Cancer Res; 2001 May; 61(10):3902-7. PubMed ID: 11358803
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake.
Todorova VK; Kaufmann Y; Luo S; Klimberg VS
Cancer Chemother Pharmacol; 2011 Feb; 67(2):285-91. PubMed ID: 20383709
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
17. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.
O'Regan RM; Gajdos C; Dardes RC; De Los Reyes A; Park W; Rademaker AW; Jordan VC
J Natl Cancer Inst; 2002 Feb; 94(4):274-83. PubMed ID: 11854389
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.
Fryar-Tita EB; Das JR; Davis JH; Desoto JA; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(3B):1393-9. PubMed ID: 17595753
[TBL] [Abstract][Full Text] [Related]
20. Playing the old piano: another tune for endocrine therapy?
Hayes DF
J Natl Cancer Inst; 2003 Nov; 95(21):1565-7. PubMed ID: 14600082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
